2014 Was a Good Year for FDA & Pharma
|
|
- Rolf Boone
- 6 years ago
- Views:
Transcription
1 Jan 2015 Vol. 14, No. 1 Pharma Marketing Network Was a Good Year for FDA & Pharma Banging Year for Drug Approvals, Wimpy Year for Enforcement Actions Author: John Mack Published by: Pharma Marketing Network publisher@pharma-mkting.com PMN
2 Vol. 14, No. 1: January 2015 Page 1 T he U.S. Food and Drug Administration (FDA) ended 2014 with a bang and a whimper. The Agency approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 2014, the greatest number since That was the bang. FDA, however, also ended the year with a whim-per. The Agency sent out only a meager 10 adver-tising enforcement letters in 2014, the fewest ever. Big Bang Approvals! As FDA approached the finish line, it hurried the approval of fifteen new drugs in December Eleven (27%) were approved in final two weeks! 2014 was a particularly good year for biologics and orphan drugs. Ten (10) new licenses to market biologic drugs were issued in That s more than any other year and represents 24% of all new drug approvals. Meanwhile, 15 orphan drugs, which treat rare diseases/disorders affecting fewer than 200,000 people in the U.S., were approved another record (see Figure 1, right). Orphan Drugs Are Where the Money Is The U.S. government has been very kind to pharma companies that develop orphan drugs. Under the 1983 Orphan Drug Act of January 1983, orphan drugs get extended marketing exclusivity, tax breaks, expedited approval by FDA, and require fewer patients in clinical trials. A few years ago, if you asked a pharmaceutical company executive why his or her company developed and marketed an orphan drug you would likely have gotten a response such as because there is an unmet medical need or something similar. Today, however, orphan drugs also meet unmet profit needs and have the potential to turn into blockbusters with annual sales over $1 billion. Banging Drug Prices Of course, to reach that milestone, the price of these drugs has to be very high. The price tag of Amgen s Blincyto (blinatumomab), approved by the FDA on December 2014 as a second-line treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, is $178,000 per twocycle course. To reach $1 billion in Blincyto sales, Amgen must find 5,617 patients. It just so happens that the number of people suffering from this form of leukemia in the U.S. is 6,000. In comparison, during Lipitor s heyday, about 1,600,000 patients were needed to generate $1 billion in sales. Just like Willie Sutton, venture capitalists know where the money is in the drug market and venture philanthropists are also getting in the game. Figure 1. FDA Drug Approvals (1994 through 2014). NME=New Molecular Entity, BLA=Biologic License Application; Source: FDA Recently, an investment company (the venture) paid the Cystic Fibrosis Foundation (the philanthropy) $3.3 billion for its future royalties from several cystic fibrosis drugs it helped finance. The foundation, however, did little to lobby for lower prices on the drugs that were developed from the research it funded. As a result, Kalydeco, a cystic fibrosis medication it funded, is one of the most expensive drugs available, at $300,000 a year.
3 Vol. 14, No. 1: January 2015 Page 2 Wimpy Enforcement While FDA hustled in December to reach a record number of drug approvals in 2014, the Agency wasn t as motivated to set any advertising enforcement records last year. For the year, FDA sent out only a meager 9 Untitled Letters and 1 Warning Letter, the fewest ever. This continues a downward trend that began almost as soon as direct-toconsumer (DTC) advertising was sanctioned by the FDA in 1997 (see Figure 2, below). Several explanations for this trend have been suggested, including: 1. Fewer drugs are being marketed 2. Pharmaceutical marketers are getting better at complying with FDA regulations. 3. FDA regulators are too busy dealing with other matters. 4. Staff cuts due to budgetary restraints 5. Fear of being sued by the pharmaceutical industry in the wake of the 2012 Caronia decision that found off-label promotion was protected by free speech 6. DTC marketers are playing it safe. 7. Rising PDUFA fees paid to FDA means less willingness to bite the hand that feeds the Agency. As already noted, 2014 was a banner year for drug approvals. However, 37% of these were for treatment of rare diseases and therefore the marketing budgets for these drugs is expected to be low. Thus, it is conceivable that the downward trend in enforcement actions is due to fewer, non-orphan drugs being marketed. But this can t be the only reason. As for item #2, it s difficult to believe pharma marketers are getting better at complying with regulations when in recent years one drug company after another has agreed to pay multi-million/billion dollar settlements to the DOJ for inappropriately, and in some cases illegally, promoting prescription drugs (see Figure 3, below). Figure 2. Trends in FDA Advertising Enforcement Actions Figure 3. Pharma Criminal & Civil Settlement Planetary System
4 Vol. 14, No. 1: January 2015 Page 3 Busy, Busy FDA Coalition for Healthcare Communication Executive Director John Kamp implied that FDA s Office of Prescription Drug promotion (OPDP) unit has been too busy working diligently on a number of policy documents, including social media guidance for it to have time to deal with such trifling matters as enforcing existing advertising and promotion regulations. He also hinted that FDA is busy contemplating policy items relating to the rights of companies to speak truthfully about the off-label uses of their products under the First Amendment. With regard to Caronia decision/off-label claims, while it is true that none of the letters issued in 2014 mentioned that violation, this is not new. Historically (between 2004 and 2013), only 4% of violations cited in FDA letters was concerned with off-label ( unapproved use ) promotion (see Figure 4, below). So, the 2012 Caronia decision, which stemmed from a 2009 conviction of Orphan Medical sales rep Alfred Caronia probably was not a factor in why fewer and fewer letters have been issued by FDA every year beginning in Note: There was a spike in 2009 and 2010, which was probably in reaction to the VIOXX fiasco during which time the FDA was under extreme pressure from Congress and the public to reign in drug pro-motions and DTC advertising in particular. trying to fit in to hold their jobs. Can anyone really name one DTC campaign that featured really great innovative marketing?, asks Meyer. When was the last time a pharma brand won awards, from outside the industry, on DTC advertising? Meyer blames pharma s conservative legal/regulatory people for preventing DTC marketers from being more innovative. He would like to see more pharma marketers focus more on innovative digital and social media channels, where there is less guidance from the FDA and thus more chance that marketers will inadvertently run afoul of the regulators. Meyer and may have a point. Based on an analysis of FDA Warning letters and 2253 forms (Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use) submitted to the FDA by pharma advertisers, I estimate that Internet promotions receive a disproportionate number of violations. This conflicts with a 2013 Eye on FDA analysis that concluded that a Warning Letter was almost three times more likely to be based on a traditional media communications vehicle than on a digital one. Figure 4. Type of Violations Cited by FDA in Warning/NOV Letters Are Pharma Marketers Playing It Safe? World of DTC Marketing blogger Rich Meyer, believes the reason for the decline in NOV letters is because of the lack of really talented marketers and those in DTC who are afraid to rock the boat and just Figure 5. PDUFA Fees Collected by FDA vs. Enforcement Letters Issued
5 Vol. 14, No. 1: January 2015 Page 4 Mark Senak of Eye On FDA looked at 676 violations in the 173 letters sent out by FDA between 2008 and 2012 and found that 57 percent (n=385) of the vehicles cited for violations were nondigital properties compared to 43 percent (n=290) involving digitalbased communications vehicles. How many of these violations are serious? Senak looked at the distribution of Warning Letters for that. Of 45 WLs [Warning Letters] issued by OPDP during this period, wrote Senak, only 12 cited digital communications vehicles while 33 were based on nondigital (traditional) communications, meaning that a Warning Letter was almost three times more likely to be based on a traditional media communications vehicle than on a digital one. Senak cites an obvious limitation of his data: one cannot say whether or not digital is over or under represented. The reason, claims Senak, is that we do not know what proportion of communications by industry is divided between digital and non-digital efforts. Senak contends that the lack of clarity respecting the rules around Internet and social media use does not appear to translate into a greater pattern of enforcement against digital media. I disagree. I believe we DO have some idea of the proportion of pharma marketing communications that are digital and nondigital. Pharma marketers must submit 2253 forms for all ads. Data from these forms suggests digital promotions are very much over represented in terms of violations and warning letters. For fiscal year 2011 (the latest full year of data), the percent of non-internet 2253 pieces reviewed by FDA varies from 72% to 80%, which means the % of Internet pieces is in the 20-28% or let s say 24% for the year o average. So 24% of promotional pieces reviewed by FDA gets 43% of the violations cited and 27% of serious warning letters sent. From this I would have to disagree with Senak and say the lack of clarity respecting the rules around Internet and social media use by pharma DOES appear to translate into a GREATER pattern of enforcement against digital media. PDUFA Fees vs. Enforcement Is it possible that the rise in Prescription Drug User Fee Act (PDUFA) payments to FDA from pharma, which now account for more than 65% of FDA s budget for the regulation of drugs, discourages the FDA from monitoring drug promotion and issuing warning letters? As shown in Figure 5, page 3, since 2002 PDUFA fees collected by the FDA have increased dramatically. This corresponds with the historically flat number of untitled/warning letters issued in the following years (except for the VIOXX spike mentioned above). I contend that in the years prior to the rise in PDUFA fees, FDA issued fewer and fewer warning letters so as not to upset the political process authorizing the future collection of the fees. Since then it has been more or less laissez-faire as the money continues to roll in. Money talks, bullshit walks.
McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?
McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the
More informationFDA COMMUNICATIONS. Oversight in a. DIGITAL era A WHITE PAPER
FDA COMMUNICATIONS Oversight in a DIGITAL era 2008-2013 A WHITE PAPER Mark S. Senak, J.D. Author, Eye on FDA Senior Vice President & Partner Fleishman-Hillard 04 / 2013 Table of Contents Summary Overview...
More informationOPDP Update on Oversight of Prescription Drug Promotion
OPDP Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration November 3, 2014 1 Topics Policy and Guidance Development
More informationOff-Label DTC Advertising
September 2016 Vol. 15, No. 4 Pharma Marketing Network www.pharmamarketingnews.com Off-Label DTC Advertising Will FDA Be Forced to Allow It? Author: John Mack Published by: Pharma Marketing Network PMN1504-01
More informationToo Much of a Good Thing?
Regulatory s Role in Reviewing External Corporate Communications Too Much of a Good Thing? By John Driscoll Every regulatory professional is a reviewer. One could even say that the majority of our work
More informationIndustry vs. FDA Regarding DTC Animation Study
December 2016 Vol. 15, No. 5 Pharma Marketing Network www.pharmamarketingnews.com Industry vs. FDA Regarding DTC Animation Study It s Unnecessary & Unscientific Author: John Mack Published by: Pharma Marketing
More informationHYPOTHETICAL SCENARIO: MINI SUMMIT II: R&D COMPLIANCE
HYPOTHETICAL SCENARIO: MINI SUMMIT II: R&D COMPLIANCE Dan Kracov, Arnold & Porter (Moderator) Sue Seferian, Johnson & Johnson Natasha Leskovsek, Cooley Michelle Shwery, Eli Lilly Pharmaceutical and Medical
More informationRegulatory Market Update: What are the major changes and differences worldwide?
Regulatory Market Update: What are the major changes and differences worldwide? Marlene E. Haffner MD, MPH, CEO Haffner Associates Orphan Drug Summit 2015 Copenhagen, Denmark September 17, 2015 Orphan
More informationFDA Scrutiny of Promotion and Advertising Practices
FDA Scrutiny of Promotion and Advertising Practices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! If you go "off label" with advertising and promotion, FDA's hammer can hit hard
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationStrategy resets to patient outcomes. The state of life sciences
Strategy resets to patient outcomes The state of life sciences New innovative products, even at a high cost, can be a great deal for society and the health care system if they cure a chronic disease. Expensive
More informationEnforcement and Policy Update from Office of Prescription Drug Promotion
Enforcement and Policy Update from Office of Prescription Drug Promotion Thomas Abrams, R.Ph., M.B.A. Director Office of Prescription Drug Promotion Food and Drug Administration November 2, 2011 1 Topics
More informationThe New DTCA Landscape
The New DTCA Landscape A Rose by Any Other Name, or Lipstick on a Pig? www.prescriptionaccess.org Direct-to-Consumer Advertising $4.7 - $5 Billion to consumers in 2006 ROI: 150%-420% Only US & NZ permit
More informationInsights into the Rare Disease Drug Approval Landscape: Trends and Current Development
Insights into the Rare Disease Drug Approval Landscape: Trends and Current Development Mike Lanthier Operations Research Analyst FDA Office of the Commissioner NORD Rare Diseases & Orphan Products Breakthrough
More information5 Mind Blowing Strategies Wayne Kelly
Note from Wayne: In 2005 I created my first info product a wonderful e-book about How to Get Featured on Radio Shows as an expert and a guest. I quickly realized I was not going to make it rich through
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance PERU This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted under
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance Peru This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted under
More informationDrug Safety and FDA Revitalization Legislation
Drug Safety and FDA Revitalization Legislation Dan Kracov August 23, 2007 FDA Regulatory and Compliance Symposium House and Senate FDA Revitalization Bills Senate: S. 1082, Food and Drug Administration
More informationOperational Considerations for Transparency. September 2011
Operational Considerations for Transparency September 2011 Current Global Regulatory Trends Type of Regulations/ Guidance Company s obligations Scope Sanctions/ Penalties State Laws Promotional spend reporting
More informationAgenda: Day 1 Schedule 8:30 AM - 9:00 AM: Registration
FDA Scrutiny of Promotion and Advertising Practices Overview: If you go "off label" with advertising and promotion, FDA's hammer can hit hard and seemingly out of the blue. Advertising and promotion for
More informationPresentation By Shelly Brunson Matthew Schratwieser Vernon Tilly Jr.
Presentation By Shelly Brunson Matthew Schratwieser Vernon Tilly Jr. Merck conducted clinical trials on the Cox 2 inhibitor Vioxx and submitted the data to the FDA. The FDA approved Vioxx for the treatment
More informationDTC Promotion and Guidance: OPDP Update. Michael Sauers Team Leader, DTC1 FDA/CDER/OPDP DTC National Conference April 12, 2012
DTC Promotion and Guidance: OPDP Update Michael Sauers Team Leader, DTC1 FDA/CDER/OPDP DTC National Conference April 12, 2012 DTC Promotion and Guidance Guidance Update Submission Totals DTC Enforcement
More informationTHE OFF-LABEL DEBATE AND FDA S SHIFTING OUTLOOK
THE OFF-LABEL DEBATE AND FDA S SHIFTING OUTLOOK Bridget M. Lankford In House Counsel Christopher W. Wasson Partner Erin Colleran Partner April 25, 2018 In-House Counsel Conference 2 Agenda Legal and Regulatory
More informationPharmaceutical Innovation and Regulatory Data Protection Friends or Foes?
Pharmaceutical Innovation and Regulatory Data Protection Friends or Foes? Meir Pugatch, EIPIN Meeting, Munich, April 2015 meir.pugatch@maastrichtuniversity.nl Presentation overview The value of pharmaceutical
More informationFDA Update on Oversight of Prescription Drug Promotion
FDA Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration November 7, 2018 Topics Medical Product Communications That
More informationEconomic Resources. Chapter 19, Section 1. For use with textbook pages
Chapter 19, Section 1 For use with textbook pages 424 427 Economic Resources KEY TERMS goods tangible products that satisfy needs and wants (page 424) services work that is performed for someone else (page
More informationSeptember 16, Via Electronic Submission
Via Electronic Submission Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Draft Guidance for Industry: Internet/Social Media Platforms: Correcting
More informationEnsuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices
Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! Federal regulation of the advertising
More informationJuly 13, Dear Secretary Price:
July 13, 2017 The Honorable Thomas E. Price, M.D. Secretary U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Secretary Price: At our meeting on May 16,
More informationInc 5000 Agency 2016, 2015 and Marketing Growth Hacks For HEALTHCARE PRACTICES
Inc 5000 Agency 2016, 2015 and 2014 5 Marketing Growth Hacks For HEALTHCARE PRACTICES 1 According to a Think with Google study, 84% of patients use both online and offline sources for healthcare research.
More informationBest Practices for Creating an Open Source Policy. Why Do You Need an Open Source Software Policy? The Process of Writing an Open Source Policy
Current Articles RSS Feed 866-399-6736 Best Practices for Creating an Open Source Policy Posted by Stormy Peters on Wed, Feb 25, 2009 Most companies using open source software know they need an open source
More informationAn Economic Analysis of Generic Drug Usage in the U.S.
September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care
More informationECONOMICS U$A PROGRAM #2 THE FIRM: HOW CAN IT KEEP COSTS DOWN?
ECONOMICS U$A PROGRAM #2 THE FIRM: HOW CAN IT KEEP COSTS DOWN? AUDIO PROGRAM TRANSCRIPT ECONOMICS U$A PROGRAM #2 THE FIRM (MUSIC PLAYS) Announcer: Funding for this program was provided by Annenberg Learner.
More informationAugust 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
August 25, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Docket No. FDA-2014-D-0758-0001 Draft Guidance for Industry on Distributing
More informationRodale s DTC th YEAR DTC STUDY
Rodale s DTC 12 th YEAR DTC Landscape DTC spending decreased 18% in 2008 DTC ad expenditures expected to decline in No ED ads until 10pm The Recession More powerful Henry Waxman Do DTC ads work? Prescription
More informationETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders
ETHICAL, LEGAL AND SOCIAL ISSUES IN DRUG DEVELOPMENT AND PHARMACOGENOMICS: Report on a Qualitative Study of the Perspectives of Canadian Stakeholders SHANNON GIBSON University of Toronto Faculty of Law
More informationThe Economics of New Drug Development: Costs, Risks, and Returns
The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationLimiting Sales Rep Access to Physicians
May 2017 Vol. 16, No. 2 Pharma Marketing Network www.pharmamarketingnews.com Limiting Sales Rep Access to Physicians Do the Benefits Outweigh the Risks? Author: John Mack Published by: Pharma Marketing
More informationCommunicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
More informationThe White House s Drug Pricing Blueprint
Debevoise In Depth The White House s Drug Pricing Blueprint May 18, 2018 On May 11, 2018, the White House released the President s Blueprint to Lower Drug Prices (the Blueprint ). Because President Trump
More informationChapter. The Implications of Patent-Term Extension for Pharmaceuticals
Chapter The Implications of Patent-Term Extension for Pharmaceuticals Chapter 4 The Implications of Patent-Term Extension for Pharmaceuticals This chapter examines the possible impact of pharmaceutical
More informationThe Science of Small Clinical Trials
The Science of Small Clinical Trials Introduction to Small Clinical Trials an Industry Perspective Simon Day, PhD Confucius (allegedly) When it is obvious that the goals cannot be reached, don t adjust
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations
More informationHow Have User Fees Affected the FDA?
HEALTH & MEDICINE How Have User Fees Affected the FDA? The 1992 FDA reform successfully reduced drug review times. Mary K. Olson Yale University D elay in the approval of new drugs has been a policy problem
More informationPhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES
PhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES P hrma GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES PREAMBLE Given the progress
More informationOff-Label Promotion: Risks, Controls and Assessment
7 th th Annual National Pharmaceutical Congress November 9, 2006 Off-Label Promotion: Risks, Controls and Assessment John T. Bentivoglio Co-Leader FDA/Healthcare Group jbentivoglio@kslaw.com 202.626.5591
More informationUS Healthcare and Pharma Industry StatPack 2018
US Healthcare and Pharma Industry StatPack 2018 Digital Ad Spending Forecast and Trends presented by This StatPack includes updated emarketer forecasts and third-party data Methodology Healthcare and Pharma
More informationRobert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation
Name and Organization: Robert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation Subject of Testimony: Food and Drug Administration Funding for Fiscal Year 2013 Point of Contact:
More informationMerck s Alignment with PhRMA DTC Principles (Updated January 30, 2009)
Merck s Alignment with PhRMA DTC Principles (Updated January 30, 2009) Effective January 1, 2006, the Pharmaceutical Research Manufacturer s Association (PhRMA) implemented the PhRMA Guiding Principles
More informationBREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D
BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationI D C T E C H N O L O G Y S P O T L I G H T
I D C T E C H N O L O G Y S P O T L I G H T C o n f r o n t i n g C h r onic Disease at the Point of M a x i m u m I mpact January 2017 Adapted from Business Strategy: Demand for IT Services Related to
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationWhat Is The Largest Issue Facing Pharmaceutical Companies Today
What Is The Largest Issue Facing Pharmaceutical Companies Today For an industry as data-intensive as pharmaceuticals, innovations in 'big data' and tackle some of the biggest issues they are facing in
More informationTopics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION
DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION Presentation to the FDA/Industry Conference sponsored by the School of Pharmacy at Temple University May 6, 2008 Topics Safety First initiative
More informationChapter 1 Executive Summary
Chapter 1 Executive Summary Chapter 1 Executive Summary INTRODUCTION Patents were designed to promote innovation by providing the right to exclude others from making, using, or selling an invention. They
More information[PDF] Network Marketing: Guide For A Successful Network Marketing Career
[PDF] Network Marketing: Guide For A Successful Network Marketing Career Network marketing is quickly becoming one of the most efficient and effective ways to earn a livable income from your own home!
More informationPatient Protection and Affordable Care Act (H.R. 3590) Approval Pathway for Biosimilar Biological Products
Approval Pathway for Biosimilar Biological Products On December 24, 2009, the U.S. Senate passed the, its version of comprehensive healthcare reform legislation. On March 21, 2010, the U.S. House of Representatives
More informationWARNING LETTER. Below is the indication and summary of the most serious and most common risks associated with the use of Ampyra. 1
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 Ron Cohen, M.D. President & Chief Executive Officer 420 Saw Mill River Road Ardsley, NY
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationYour Business. with. Inbound Marketing
Your Business with Inbound Marketing Table of contents So What is Inbound Marketing? Is it Just a Fad? Inbound marketing in a nutshell What inbound marketing can do for your business? But is inbound marketing
More informationFDA Compliance Enforcement Actions: What you need to know for clinical device trials
FDA Compliance Enforcement Actions: What you need to know for clinical device trials The 3 rd Annual FDA Regulatory and Compliance Symposium Track 3-3 Pharma Product Development and Clinical Trials August
More informationNPD in an environment of range rationalisation.
NEW PRODUCT STUDY: NPD in an environment of range rationalisation. NICHOLAS HILL ADAM VINE-HALL TIM EALES OCTOBER 2016 New Products - What s the Story? The number of items stocked in an average Supermarket
More informationInnovative Marketing Ideas That Work
INNOVATIVE MARKETING IDEAS THAT WORK Legal Disclaimer: While all attempts have been made to verify information provided in this publication, neither the Author nor the Publisher assumes any responsibility
More information10 Things To Never Say
10 Things To Never Say When Delegating PRACTICAL TOOLS 10 Things To Never Say When Delegating / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
More informationSeptember 16, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 16, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2014-D-0447: Draft Guidance for Industry on Internet
More informationTHE INDEPENDENT PHARMACIST S GUIDE TO THE ON-SITE AUDIT Amanda C. Fields, General Counsel for American Pharmacies (APRx) American Pharmacies 2011
THE INDEPENDENT PHARMACIST S GUIDE TO THE ON-SITE AUDIT Amanda C. Fields, General Counsel for American Pharmacies (APRx) American Pharmacies 2011 Introduction As the Texas pharmacists know, audits by insurance
More informationPRIZE PROMOTIONS AROUND THE WORLD. Germany
PRIZE PROMOTIONS AROUND THE WORLD Germany Downloaded: 21 Jun 2018 ABOUT Welcome to the third edition of DLA Piper's Guide to Prize Promotions Around the World. Prize promotions are a popular marketing
More informationEffective Dates: Affected Customers: Metagenics reserves the right to determine which of its Internet Policies applies to each Customer.
Effective Dates: Affected Customers: Metagenics Internet Policy Practitioner-Patient Sales ONLY November 1, 2016 - until further notice U.S. Customers Customers selling predominantly online to U.S. end-users
More informationStem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
More informationINTERNET MARKETING AGENCY IN 2017
INDUSTRY REPORT STATE OF THE INTERNET MARKETING AGENCY IN 2017 STATE OF THE INTERNET MARKETING AGENCY IN 2017 1 INTRODUCTION Little-known fact: about a third of WordStream s customer base consists not
More informationThe BIG question: What s different about a customer-driven business transformation?
The BIG question: What s different about a customer-driven business transformation? With customers holding more power than ever before, some transformation leaders are using the customer perspective to
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationDiscuss the characteristics of a private enterprise system. Describe the economic freedoms that exist in a private enterprise system.
Every society develops a system for making decisions about how it will use its resources to meet the needs and wants of its people. Each of these economic systems must answer these three basic questions:
More informationTexas Board of Professional Engineers Professional Practice Update / Ethics
Texas Board of Professional Engineers Professional Practice Update / Ethics George P. Hartmann, P.E. Licensing Project Manager September, 2013 Agenda Responsibility / Professionalism and Ethics Laws/Rules/Scenarios
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationa physicians guide to security risk assessment
PAGE//1 a physicians guide to security risk assessment isalus healthcare isalus healthcare a physicians guide to security risk assessment table of contents INTRO 1 DO I NEED TO OUTSOURCE MY SECURITY RISK
More informationFDA Drug Safety Changes Impact On Pharma
FDA Drug Safety Changes Impact On Pharma Cole Werble Kevin Editor-in-Chief Spurway, Vp of The Marketing RPM Report 10.09.06 November 8, 2007 Key Takeaways New Drug Safety Law: A Positive Turning Point
More informationAmericas retail report
Americas retail report Redefining loyalty for retail June 2015 Redefining loyalty for retail Today, American consumers have more shopping choices than ever before. They have access to more diverse retailers
More informationTopics Covered. FDA s Role in Expediting the Development of Novel Medical Products. How a Regulatory Agency Comes into Existence 3/5/2018
FDA s Role in Expediting the Development of Novel Medical Products Peter Marks, M.D., Ph.D. Director Center for Biologics Evaluation and Research Topics Covered Brief history of FDA Expediting product
More information7 MISTAKES PEOPLE MAKE WHEN BUYING A FRANCHISE.
WHITEPAPER 7 MISTAKES PEOPLE MAKE WHEN BUYING A FRANCHISE. BUYING A FRANCHSIE CAN BE A DAUNTING PROCESS AND IT IS IMPORTANT TO AVOID THESE SEVEN MISTAKES. INTRODUCTION Michael Gerber of The E-Myth talks
More informationClarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases
Clarification of Orphan Designation of Drugs and Biologics for Pediatric Subpopulations of Common Diseases Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration
More informationSTRATEGY #1: USE BOOTSTRAPPING TO MAKE THE MOST OF WHAT YOU HAVE 4 PROVEN STRATEGIES TO SUCCEED
4 PROVEN STRATEGIES TO SUCCEED To be successful in business, you need to turn your resources into profits. Unfortunately, many entrepreneurs consider money the only resource that will make their business
More informationLaw firms & the 7 Ps. Why is there no real legal marketing?
Law firms & the 7 Ps. Why is there no real legal marketing? The past. I first joined a law firm in 2006. At that point most law firm marketing & business development teams comprised marketing generalists.
More informationStrategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002
Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Gill Butler has worked in the pharmaceutical industry for 21 years,
More informationJohan Christenson MD; PhD Partner Farmasidagene 2014 Oslo
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo 1 HealthCap Focuses on Breakthrough Therapeutics Significant resource base Partners with profound sector experience Six MD PhD s Extensive network
More informationFDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development. October 4, 2004
FDA Critical Path Initiative: Closing Productivity Gap in Medical Product Development October 4, 2004 1 What is the problem? Trends in Biomedical Research Spending R&D Spending Has Accelerated Since 1990
More informationBuilding Biotech Technology Transfer Opportunities
For a clearer market perspective Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success Report Price Publication date 1995/ 2885/$3835 March 2010 H E A L T H C
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More informationMake the Climate Change Bill Count: How to Meet your MP
If we choose, we can make our politicians take the action needed. They cannot resist us all. Together, we can stop climate chaos Page 2 Autumn 2007 is a critical time for the I Count campaign. Through
More informationInventing for profit
How to Guide Inventing for profit An inventor s guide Contents 3 Idea protection Available forms of protection What is a utility patent? What does a utility patent involve? How much does a utility patent
More informationCEOCFO Magazine. Andy Williams Co-Founder and CEO. Medicine Man Technologies, Inc. (OTCQX: MDCL)
CEOCFO Magazine ceocfointerviews.com All rights reserved Issue: January 14, 2019 A leading Global Cannabis Consulting Services Company with their own Products, Facilities, Cultivation Technology and Book
More informationNew Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
More informationRosie s Top Ten Tips for Taking Your. Big Jam Hobby to the. Next Level
Rosie s Top Ten Tips for Taking Your Big Jam Hobby to the Next Level INTRO There are undoubtedly pitfalls but with my support and experience you can learn not to fall into all of them. I have been making
More informationStrategic Ad Campaign
Strategic Ad Campaign Promote and Explain PBM Value in the Rx Drug Pricing Debate US House Majority Leader Kevin McCarthy Recognition Drug Benefit Solutions Marketing Category: Integrated Campaign Drug
More informationInc 5000 Agency 2016, 2015 and Marketing Growth Hacks to Help Plastic Surgeons GROW THEIR PRACTICE
Inc 5000 Agency 2016, 2015 and 2014 5 Marketing Growth Hacks to Help Plastic Surgeons GROW THEIR PRACTICE 1 As important as it is to pursue traditional marketing channels to grow your practice, it s equally
More informationPDUFA & FDA Legislation
PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Pfizer Dan Kracov, Arnold & Porter Dan Carpenter, Harvard Dept. of Government 1 Disclaimer The views expressed
More information